{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031383","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.796679+00:00","generated_at":"2026-06-22T00:00:16.751178+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Indaptus Q3 2022: cash $28.5M, loss $0.42/share; Decoy20 Phase 1 to start Q4 2022","bullets":["Cash, equivalents and marketable securities of $28.5M as of Sep 30, 2022, down from $39.1M at Dec 31, 2021.","R&D expenses of $1.6M in Q3 2022, up $900K vs Q3 2021, driven by Phase 1 trial preparation and manufacturing costs.","G&A expenses of $2.0M in Q3 2022, down $700K vs Q3 2021, due to lower merger-related costs.","Loss per share of $0.42 in Q3 2022 vs $0.81 in Q3 2021; net loss of $2.3M for the quarter.","Phase 1 trial of Decoy20 for solid tumors remains on track to initiate in Q4 2022 after FDA IND clearance in May."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031383","json":"https://secwatch.observer/filing/0001493152-22-031383.json","markdown":"https://secwatch.observer/filing/0001493152-22-031383.md","text":"https://secwatch.observer/filing/0001493152-22-031383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/0001493152-22-031383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:00:16.751178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8b790db1da1398f64351d1090a88731f7f0f993","claim":"Indaptus Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s results of operations for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222031383/0001493152-22-031383-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}